Sugi Predict

Sugi Predict / Targets / PCSK7

PCSK7

Proprotein convertase subtilisin/kexin type 7 · Q16549 · PCSK7 on Sugi Atlas →

1,291 patent compounds predicted against PCSK7, 1,090 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7354624 SCHEMBL7354624 0.69 2/20
SCHEMBL7349467 SCHEMBL7349467 0.61 2/20
SCHEMBL5107449 SCHEMBL5107449 0.58 2/20
SCHEMBL2417869 SCHEMBL2417869 0.58 2/20
SCHEMBL1648026 SCHEMBL1648026 0.53 2/20
SCHEMBL3778823 SCHEMBL3778823 0.51 2/20
SCHEMBL7351830 SCHEMBL7351830 0.50 2/20
SCHEMBL7354341 SCHEMBL7354341 0.50 2/20
SCHEMBL4801386 SCHEMBL4801386 0.49 2/20
SCHEMBL1649890 SCHEMBL1649890 0.47 2/20
SCHEMBL5103338 SCHEMBL5103338 0.46 2/20
SCHEMBL429446 SCHEMBL429446 0.44 2/20
SCHEMBL5328547 SCHEMBL5328547 0.43 2/20
Warfarin Warfarin (SCHEMBL3689) 1.00 1/20
Dicumarol Dicumarol (SCHEMBL33891) 1.00 1/20
Warfarin Warfarin (SCHEMBL662875) 1.00 1/20
Warfarin Warfarin (SCHEMBL2139452) 1.00 1/20
Warfarin Warfarin (SCHEMBL3792087) 1.00 1/20
Warfarin Warfarin (SCHEMBL4439794) 1.00 1/20
Dicumarol Dicumarol (SCHEMBL7454901) 1.00 1/20

Clinical trials — most relevant to PCSK7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lipid Management in Renal Transplant Recipients Using Evolocumab. PHASE4COMPLETED
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI PHASE4ACTIVE_NOT_RECRUITING
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke PHASE4NOT_YET_RECRUITING
Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO) PHASE4UNKNOWN
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients PHASE3COMPLETED
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH PHASE3ACTIVE_NOT_RECRUITING
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event PHASE3ACTIVE_NOT_RECRUITING
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) PHASE3COMPLETED
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia PHASE3UNKNOWN
Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia PHASE3COMPLETED
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) PHASE3COMPLETED
Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia PHASE2COMPLETED
A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia PHASE2ACTIVE_NOT_RECRUITING
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) PHASE1NOT_YET_RECRUITING
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level PHASE1COMPLETED
A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease EARLY_PHASE1NOT_YET_RECRUITING
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab® nanUNKNOWN
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
A Registration Study for Familial Hypercholesterolemia in Taiwan nanUNKNOWN
The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial nanACTIVE_NOT_RECRUITING
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease nanRECRUITING
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids nanRECRUITING
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom nanRECRUITING
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States nanCOMPLETED
To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy nanUNKNOWN
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction nanUNKNOWN
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment nanUNKNOWN
Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance nanCOMPLETED
Development of a Prognostic Tool for the Stratification of Cardiovascular Risk in Patients With Ischemic Stroke nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PCSK7 binder may also engage these)

ProteinNameSimilarity
Q61139 — 1.000 Q61139 →
Q62849 — 1.000 Q62849 →
P29121 — 0.990 P29121 →
Q78EH2 — 0.987 Q78EH2 →
A8T658 — 0.987 A8T658 →
A8T688 — 0.987 A8T688 →
A8T682 — 0.985 A8T682 →
A8T666 — 0.984 A8T666 →
P59996 — 0.983 P59996 →
A8T662 — 0.983 A8T662 →
PCSK9 Proprotein convertase subtilisin/kexin type 9 0.983 landscape →
Q80W65 — 0.983 Q80W65 →
P23377 — 0.982 P23377 →
A8T695 — 0.982 A8T695 →
Q63415 — 0.982 Q63415 →
PCSK6 Proprotein convertase subtilisin/kexin type 6 0.981 landscape →
FURIN Furin 0.981 landscape →
A8T650 — 0.981 A8T650 →
A8T672 — 0.981 A8T672 →
A8T6A6 — 0.980 A8T6A6 →
Q6UW60 — 0.980 Q6UW60 →
A8T655 — 0.980 A8T655 →
A8T644 — 0.980 A8T644 →
Q28193 — 0.980 Q28193 →
P23188 — 0.979 P23188 →
A8T6A1 — 0.978 A8T6A1 →
A8T677 — 0.978 A8T677 →
Q9DA79 — 0.978 Q9DA79 →
Q8R4K8 — 0.977 Q8R4K8 →
Q96SM3 — 0.977 Q96SM3 →